EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists

Zoe Tasma iD, Andrew Siow, Paul W R Harris, Margaret A Brimble, Debbie L Hay iD, Christopher S Walker

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14916 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Zoe Tasma und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, The University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Pituitary Adenylate Cyclase-Activating Polypeptide, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Research Council of New Zealand, Marsden Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to provide proof‐of‐concept that multi‐receptor antagonist peptides can be generated by covalently linking independent antagonist peptides that block calcitonin gene‐related peptide (CGRP 8‐37 ) or pituitary adenylate cyclase‐activating peptide (PACAP)/vasoactive intestinal peptide (VIP) (PACAP 6‐38 ) activity.

Background

The neuropeptides CGRP and PACAP are implicated in migraine and pain pathogenesis. CGRP and PACAP are elevated during a migraine attack, and following infusion of either peptide, patients develop migraine‐like attacks. This indicates that targeting both these systems may provide therapeutic benefits. Mechanistic studies suggest that these peptides largely act independently from one another. Therefore, blocking the activity of both CGRP and PACAP simultaneously could provide a clinical advantage over individual blockade. One strategy is to develop a single antagonist capable of inhibiting the signaling of both CGRP and PACAP receptors, a multi‐receptor antagonist. N‐terminal truncation of CGRP and PACAP generates the antagonists CGRP 8‐37 and PACAP 6‐38 , respectively. These are commonly used as research tools for the CGRP and PACAP receptors. These peptide antagonists were, therefore, used as the basis for the design of multi‐receptor antagonists against the CGRP and PACAP receptors and to test their functionality in vitro.

Methods

To generate multi‐receptor antagonists, CGRP 8‐37 was linked through 1,3‐dipolar cycloaddition using click chemistry to PACAP 6‐38 at amino acid residues 21, 34, or 38. The ability of these multi‐receptor antagonists to block CGRP activity (CGRP and AMY 1 receptors) and PACAP‐38, PACAP‐27, and VIP activity (PAC 1 , VPAC 1 , and VPAC 2 receptors) was then characterized in transfected Cos7 cells. The peptides were then further examined in pain‐relevant rat spinal cord cultures, as a model of endogenous receptors.

Results

Multi‐receptor antagonists were successfully generated, displaying similar antagonist potency to their parental antagonists in both transfected Cos7 cells and in spinal cord cultures. Interestingly, CGRP 8‐37 linked to position 38 of PACAP 6‐38 was a more potent antagonist of CGRP activity than CGRP 8‐37 .

Conclusion

This study provides proof‐of‐concept evidence for the development of potent multi‐receptor antagonists capable of blocking both CGRP and PACAP activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary Adenylate Cyclase-Activating PolypeptideCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsReceptors, Pituitary Adenylate Cyclase-Activating PolypeptidePeptide FragmentsDrug DevelopmentAnimalsRatsHumansMigraine DisordersMale

Stichwörter der Autor:innen

G protein‐coupled receptorantagonistcalcitonin gene‐related peptideheadachemigrainepituitary adenylate cyclase‐activating peptide

Substanzen

Pituitary Adenylate Cyclase-Activating PolypeptideCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsReceptors, Pituitary Adenylate Cyclase-Activating PolypeptidePeptide Fragmentspituitary adenylate-cyclase-activating-peptide (6-38)calcitonin gene-related peptide (8-37)

Autor:innen und Institutionen

  • School of Biological Sciences, The University of Auckland, Auckland, New Zealand.
  • School of Chemical Sciences, The University of Auckland, Auckland, New Zealand.
  • Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.
  • Department of Pharmacology and Toxicology, The University of Otago, Dunedin, New Zealand.

ORCID-Profile: Zoe Tasma, Debbie L Hay

Förderung

  • Health Research Council of New Zealand
  • Marsden Fund

Zitieren

APA

Tasma, Z., Siow, A., Harris, P. W. R., Brimble, M. A., Hay, D. L., & Walker, C. S. (2025). Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14916

Vancouver

Tasma Z, Siow A, Harris PWR, Brimble MA, Hay DL, Walker CS. Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14916

BibTeX
@article{Tasma2025,
  author = {Tasma, Zoe and Siow, Andrew and Harris, Paul W R and Brimble, Margaret A and Hay, Debbie L and Walker, Christopher S},
  title = {Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14916}
}
Kostenlos starten →